Isn't this even better news b/c it now just supports MNTA's technology advantage than before? Sure before one could conjecture based on their approval first, but unless tested in court, one never knows.
Quite right, IMO. Assuming the PI is not overturned via an emergency appeal, on any rational basis MNTA’s business is now worth more than it was before Amphastar’s FDA approval.